Acumen Pharmaceuticals (ABOS) Competitors $1.43 +0.01 (+0.70%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS vs. NBTX, RNAC, RCKT, CADL, AMRN, INBX, NGNE, IVA, FDMT, and AVIRShould you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Nanobiotix (NBTX), Cartesian Therapeutics (RNAC), Rocket Pharmaceuticals (RCKT), Candel Therapeutics (CADL), Amarin (AMRN), Inhibrx Biosciences (INBX), Neurogene (NGNE), Inventiva (IVA), 4D Molecular Therapeutics (FDMT), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry. Acumen Pharmaceuticals vs. Its Competitors Nanobiotix Cartesian Therapeutics Rocket Pharmaceuticals Candel Therapeutics Amarin Inhibrx Biosciences Neurogene Inventiva 4D Molecular Therapeutics Atea Pharmaceuticals Nanobiotix (NASDAQ:NBTX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations. Is NBTX or ABOS more profitable? Nanobiotix's return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NanobiotixN/A N/A N/A Acumen Pharmaceuticals N/A -81.39%-61.96% Does the media favor NBTX or ABOS? In the previous week, Acumen Pharmaceuticals had 11 more articles in the media than Nanobiotix. MarketBeat recorded 14 mentions for Acumen Pharmaceuticals and 3 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 0.94 beat Acumen Pharmaceuticals' score of -0.19 indicating that Nanobiotix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nanobiotix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate NBTX or ABOS? Nanobiotix currently has a consensus target price of $8.00, suggesting a potential downside of 9.09%. Acumen Pharmaceuticals has a consensus target price of $6.33, suggesting a potential upside of 342.89%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Nanobiotix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nanobiotix 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in NBTX or ABOS? 38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings and valuation, NBTX or ABOS? Nanobiotix has higher revenue and earnings than Acumen Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNanobiotix$39.18M10.77-$73.73MN/AN/AAcumen PharmaceuticalsN/AN/A-$102.33M-$2.28-0.63 Which has more risk and volatility, NBTX or ABOS? Nanobiotix has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. SummaryNanobiotix and Acumen Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABOS vs. The Competition Export to ExcelMetricAcumen PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.62M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.6320.7630.8625.25Price / SalesN/A231.85403.9088.50Price / CashN/A41.5625.2228.45Price / Book0.479.759.516.00Net Income-$102.33M-$54.74M$3.26B$265.34M7 Day Performance0.70%8.09%4.49%2.81%1 Month Performance-4.67%7.70%5.18%1.50%1 Year Performance-44.36%18.13%31.98%25.46% Acumen Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABOSAcumen Pharmaceuticals3.0447 of 5 stars$1.43+0.7%$6.33+342.9%-44.7%$86.62MN/A-0.6320News CoverageEarnings ReportAnalyst RevisionNBTXNanobiotix0.8208 of 5 stars$6.80flat$8.00+17.6%+59.8%$320.51M$39.18M0.00100News CoverageShort Interest ↑Gap UpHigh Trading VolumeRNACCartesian Therapeutics2.3726 of 5 stars$12.48+1.2%$40.00+220.5%-20.3%$320.02M$38.91M-0.2464RCKTRocket Pharmaceuticals4.8468 of 5 stars$3.07+2.7%$17.87+482.0%-83.9%$319.29MN/A-1.17240CADLCandel Therapeutics2.6082 of 5 stars$6.31+0.3%$22.00+248.7%+15.6%$315.15MN/A-4.7160Earnings ReportAMRNAmarin0.254 of 5 stars$15.38+1.5%$12.00-22.0%+26.9%$313.92M$228.61M-4.19360INBXInhibrx Biosciences1.6567 of 5 stars$21.80+0.9%N/A+87.2%$312.68M$200K0.19166News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↓NGNENeurogene2.001 of 5 stars$21.72-0.3%$46.17+112.6%-41.4%$310.63M$925K-4.9990Earnings ReportIVAInventiva3.5953 of 5 stars$3.24+0.6%$10.40+221.0%+98.2%$308.03M$9.95M0.00100Short Interest ↓Gap DownHigh Trading VolumeFDMT4D Molecular Therapeutics2.0553 of 5 stars$5.24-18.4%$29.56+464.0%-49.3%$297.40M$40K-1.65120Earnings ReportAnalyst RevisionAVIRAtea Pharmaceuticals2.2769 of 5 stars$3.53+1.7%$6.00+70.0%-4.9%$296.96MN/A-2.1470 Related Companies and Tools Related Companies NBTX Competitors RNAC Competitors RCKT Competitors CADL Competitors AMRN Competitors INBX Competitors NGNE Competitors IVA Competitors FDMT Competitors AVIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABOS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access